Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow RVTY
Revvity Inc. (RVTY) Return on assets
Revvity Inc.'s return on assets over the twelve months to 30 June 2026 was 1.95%, down 0.0 percentage points from fiscal 2025 (1.96%). Over the past ten years it has ranged from 1.96% (fiscal 2025) to 10.0% (fiscal 2020) — the current reading is the lowest in ten years. That is above the Diagnostics & Research industry median of −6.71% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 1.96% | (0.12) |
| FY2024 | 2.08% | (2.93) |
| FY2023 | 5.01% | 1.10 |
| FY2022 | 3.91% | (4.31) |
| FY2021 | 8.22% | (1.82) |
| FY2020 | 10.0% | 6.40 |
| FY2019 | 3.64% | (0.30) |
| FY2018 | 3.94% | (1.70) |
| FY2017 | 5.64% | 0.09 |
| FY2016 | 5.55% | 0.43 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| MEDP Medpace Holdings, Inc. compare | 27.1% |
| QGEN QIAGEN N.V. compare | 6.99% |
| DGX Quest Diagnostics Incorporated compare | 6.43% |
| LH Labcorp Holdings Inc. compare | 5.48% |
| RVTY Revvity Inc. | 1.95% |
| ICLR ICON PLC compare | 0.26% |
| CRL Charles River Laboratories International, Inc. compare | −3.16% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| GH Guardant Health, Inc. compare | −28.0% |
| Diagnostics & Research industry median | −6.71% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on RVTY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement